secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001104659-23-057152
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma Q1 2023 net loss narrows to $22.1M; YUPELRI sales up 8% to $47M
--------------------------------------------------------------------------------

- Q1 GAAP net loss from continuing ops $22.1M vs $40.3M; non-GAAP net loss $14.9M vs $25.2M.
- YUPELRI net sales (Viatris) $47M, +8% YoY; Theravance's 35% share $16.4M.
- $215M of $325M buyback completed; $110M remaining; on track to finish by year-end.
- CYPRESS Phase 3 study of ampreloxetine in MSA-nOH actively recruiting; enrollment expected H2 2024.
- Jim Kelly (Weiss Asset Mgmt) appointed to Board; TRELEGY milestone $50M if 2023 global sales ≥ $2.9B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923057152/0001104659-23-057152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923057152/tm2314872d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-057152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer